Details

Autor(en) / Beteiligte

• Richeldi, Luca
• du Bois, Roland M
• Raghu, Ganesh
• Azuma, Arata
• Brown, Kevin K
• Costabel, Ulrich
• Cottin, Vincent
• Flaherty, Kevin R
• Hansell, David M
• Inoue, Yoshikazu
• Kim, Dong Soon
• Kolb, Martin
• Nicholson, Andrew G
• Noble, Paul W
• Selman, Moisés
• Taniguchi, Hiroyuki
• Brun, Michèle
• Le Maulf, Florence
• Girard, Mannaïg
• Stowasser, Susanne
• Schlenker-Herceg, Rozsa
• Disse, Bernd
• Collard, Harold R

Titel

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Ist Teil von

• The New England journal of medicine, 2014-05, Vol.370 (22), p.2071-2082

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• In this randomized, placebo-controlled trial, treatment with nintedanib, an intracellular inhibitor of multiple tyrosine kinases, led to a reduced rate of loss of forced vital capacity in patients with idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is a fatal lung disease characterized by worsening dyspnea and progressive loss of lung function. 1 A decline in forced vital capacity (FVC) is consistent with disease progression and is predictive of reduced survival time. 1 – 6 Idiopathic pulmonary fibrosis is believed to arise from an aberrant proliferation of fibrous tissue and tissue remodeling due to the abnormal function and signaling of alveolar epithelial cells and interstitial fibroblasts. 7 The activation of cell-signaling pathways through tyrosine kinases such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of . . .